

Week of February 17

Tuesday, February 18

1:00 p.m.

Briefing on BPR Project on
Redesigned Materials Licensing
Process (Public Meeting)
(Contact: Don Cool, 301-415-7197)

2:30 p.m.

Briefing on Analysis of Quantifying
Plant Watch List Indicators (Arthur
Andersen Study) (Public Meeting)
(Contact: Rick Barrett, 301-415-7482)

4:00 p.m.

Discussion of Interagency Issues
(Closed—Ex. 9)

Wednesday, February 19

2:00 p.m.

Briefing on Millstone and Marine
Yankee Lessons Learned (Public
Meeting)
(Contact: Steve Stein, 301-415-1296)

3:30 p.m.

Affirmation Session (Public Meeting)
(if needed)

Thursday, February 20

2:00 p.m.

Briefing on EEO Program (Public
Meeting)
(Contact: Ed Tucker, 301-415-7382)

Week of February 24—Tentative

Wednesday, February 26

11:30 a.m.

Affirmation Session (Public Meeting)
(if needed)

Week of March 3—Tentative

There are no meetings scheduled for
the Week of March 3.

Week of March 10—Tentative

Monday, March 10—Tentative

2:30 p.m.

Briefing on Implementation of
Maintenance Rule, Revised
Regulatory Guide, and
Consequences (Public Meeting)

Thursday, March 13—Tentative

11:30 p.m.

Affirmation Session (Public Meeting)
(if needed)

The schedule for Commission
Meetings is subject to change on short
notice. To verify the status of meetings
call (recording)—(301) 415-1292.
Contact person for more information:
Bill Hill (301) 415-1661.

* * * * *

ADDITIONAL INFORMATION:

By a vote of 5-0 on February 11, the
Commission determined pursuant to
U.S.C. 552b(e) and 10 CFR Sec. 9.107(a)
of the Commission's rules that "Meeting

with Republic of Korea National
Assembly Delegation (Closed—Ex. 9)"
be held on February 11, and on less than
one week's notice to the public.

By a vote of 4-0 on February 13, the
Commission determined pursuant to
U.S.C. 552b(e) and 10 CFR Sec. 9.107(a)
of the Commission's rules that
"Affirmation of Louisiana Energy
Services (Claiborne Enrichment Center);
Atomic Safety and Licensing Board
Partial Initial Decision (Resolving
Contentions J.4, K, and Q), LBP-96-25"
be held on February 13, and on less than
one week's notice to the public.

* * * * *

The NRC Commission Meeting
Schedule can be found on the Internet
at: <http://www.nrc.gov/SECY/smj/schedule.htm>.

This notice is distributed by mail to
several hundred subscribers; if you no
longer wish to receive it, or would like
to be added to it, please contact the
Office of the Secretary, Attn: Operations
Branch, Washington, D.C. 20555 (301-
415-1661).

In addition, distribution of this
meeting notice over the internet system
is available. If you are interested in
receiving this Commission meeting
schedule electronically, please send an
electronic message to wmh.@nrc.gov or
dkw@nrc.gov.

* * * * *

Dated: February 14, 1997.
William M. Hill, Jr.,
SECY Tracking Officer, Office of the
Secretary.

[FR Doc. 97-4218 Filed 2-14-97; 2:05 pm]

BILLING CODE 7590-01-M

PRESIDENTIAL ADVISORY COMMITTEE ON GULF WAR VETERANS' ILLNESSES

Meeting

AGENCY: Presidential Advisory
Committee on Gulf War Veterans'
Illnesses.

ACTION: Notice of open meeting.

SUMMARY: Under the provisions of the
Federal Advisory Committee Act, this
notice is hereby given to announce an
open meeting of the Presidential
Advisory Committee on Gulf War
Veterans' Illnesses.

DATES: March 18, 1997, 8:30 a.m.-3:30
p.m.

PLACE: Wyndham Hotel, 215 W. South
Temple, Salt Lake City, UT 84101.

SUPPLEMENTARY INFORMATION: The
President established the Presidential
Advisory Committee on Gulf War
Veterans' Illnesses by Executive Order

12961, May 26, 1995, and extended its
tenure by Executive Order 13034,
January 30, 1997. The purpose of this
committee is to review and provide
recommendations on the government's
investigation of possible chemical and
biological weapons exposure incidents
during the Gulf War and on
implementation of the Committee's
prior recommendations. The committee
reports to the President through the
Secretary of Defense, and Secretary of
Health and Human Services, and the
Secretary of Veterans Affairs. The
committee members have expertise
relevant to the functions of the
committee and are appointed by the
President from non-Federal sectors.

Tentative Agenda*Tuesday, March 18, 1997*

8:30 a.m. Call to order and opening
remarks
8:35 a.m. Committee and staff
discussion of charge
8:50 a.m. Public comment
10:00 a.m. Break
10:15 a.m. Committee and staff
discussion: Implementation plan for
Final Report recommendations
10:30 a.m. Briefings: Overview of
ongoing and new DOD activities
11:10 a.m. Briefings: Status of DOD's
chemical and biological warfare
agent case investigations
11:50 a.m. Briefings: Activities related
to Khamisiyah
12:30 p.m. Lunch
1:30 p.m. Briefings: Activities related to
Khamisiyah (cont.)
3:15 p.m. Committee and staff
discussion: Next steps
3:30 p.m. Meeting adjourned
A final agenda will be available at the
meeting.

Public Participation

The meeting is open to the public.
Members of the public who wish to
make oral statements should contact the
Advisory Committee at the address or
telephone number listed below at least
five business days prior to the meeting.
Reasonable provisions will be made to
include on the agenda presentations
from individuals who have not yet had
an opportunity to address the Advisory
Committee. Priority will be given to
Gulf War veterans whose accounts of
firsthand experience with chemical and
biological warfare agent detections
previously have not been conveyed to
the Committee. The Advisory
Committee Chair is empowered to
conduct the meeting in a fashion that
will facilitate the orderly conduct of
business. People who wish to file
written statements with the Advisory
Committee may do so at any time.

FOR FURTHER INFORMATION CONTACT:

Michael E. Kowalok, Presidential Advisory Committee on Gulf War Veterans' Illnesses, 1411 K Street, NW., suite 1000, Washington, DC 20005, Telephone: (202) 761-0066, Fax: (202) 761-0310.

Dated: February 13, 1997.

C.A. Bock,

Federal Register Liaison Officer, Presidential Advisory Committee on Gulf War Veterans' Illnesses.

[FR Doc. 97-4043 Filed 2-18-97; 8:45 am]

BILLING CODE 3610-76-M

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Rel. No. 22507; 812-10334]

WEBS Index Fund, Inc., et al; Notice of Application

February 12, 1997.

AGENCY: Securities and Exchange Commission ("SEC").

ACTION: Notice of application for exemption Under the Investment Company Act of 1940 ("Act").

APPLICANTS: WEBS Index Fund, Inc. (the "Fund")¹ and Barclays Global Fund Advisors (the "Adviser")².

RELEVANT ACT SECTIONS: Order requested under section 17(d) of the Act and rule 17d-1 thereunder.

SUMMARY OF APPLICATION: Applicants seek an order that would permit the series of the fund to pool some or all of their uninvested cash balances and the cash collateral they receive in connection with securities lending activities ("Cash Collateral") in one or more joint accounts ("Joint Accounts") that invest in certain short-term high quality debt securities ("Short-Term Investments")

FILING DATES: The application was filed on September 13, 1996, and amended on December 27, 1996. Applicants have agreed to file an additional amendment during the notice period, the substance of which is incorporated herein.

HEARING OR NOTIFICATION OF HEARING: An order granting the application will be issued unless the SEC orders a hearing. Interested persons may request a hearing by writing to the SEC's Secretary and serving applicants with a copy of the request, personally or by mail. Hearing requests should be

received by the SEC by 5:30 p.m. on March 10, 1997 and should be accompanied by proof of service on applicants, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request such notification by writing to the SEC's Secretary.

ADDRESSES: Secretary, SEC, 450 Fifth Street, N.W., Washington, D.C. 20549. Applicants: WEBS Index Fund, Inc., c/o PFPC, Inc., 400 Bellevue Parkway, Wilmington, Delaware 19809; BZW Barclays Global Fund Advisors, 45 Fremont Street, San Francisco, California 94105.

FOR FURTHER INFORMATION CONTACT:

Courtney S. Thornton, Senior Counsel, at (202) 942-0583, or Mary Kay Ferch, Branch Chief, at (202) 942-0564 (Division of Investment Management, Office of Investment Company Regulation).

SUPPLEMENTARY INFORMATION: The following is a summary of the application. The complete application may be obtained for a fee from the SEC's Public Reference Branch.

Applicants' Representatives

1. The Fund, a Maryland corporation, is an open-end management investment company that currently offers seventeen series (the "Series").³ The Adviser provides investment advisory services for all of the Series.

2. The investment objective of each of the Series is to provide investment results that correspond generally to the aggregate price and yield performance of publicly traded securities in particular markets, as represented by foreign equity securities indexes compiled by Morgan Stanley Capital International (each, an "MSCI Index"). Each Series seeks to remain fully invested in a pool of equity securities the performance of which approximates that of the relevant MSCI Index. In addition, each Series may lend its portfolio securities to approved brokers, dealers, and other financial institutions. The Custodian serves as the lending agent of the Fund and, in that capacity, will share with the respective Series any net income earned

³ Shares of the Series ("World Equity Benchmark Shares" or "WEBS") are issued only in large aggregations of WEBS known as "Creation Units." WEBS are neither offered nor redeemed by the Series in less than Creation Unit aggregations, but WEBS may be bought or sold in smaller aggregations in the secondary market on the American Stock Exchange, where WEBS are listed and traded. Additional Series are expected to be added from time to time, and would be subject to the requested order.

on invested Cash Collateral in the proportion agreed between the Custodian and the Series from time to time.⁴

3. Subject to guidelines adopted by the board of directors of the Fund (the "Board") and such additional limits as may be established by the Adviser, each Series may invest uncommitted cash balances and Cash Collateral temporarily in the following Short-Term Investments: (a) Obligations of the U.S. Government and its agencies and instrumentalities; (b) commercial paper rated Prime-1 by Moody's Investors Services, Inc. or A-1 by Standard & Poor's Corporation ("Commercial Paper"); (c) bank certificates of deposit and bankers' acceptances; (d) repurchase agreements collateralized by the foregoing securities;⁵ (e) participation interests in such securities; and (f) shares of unaffiliated money market funds (subject to applicable limits under the Act). The maximum possible maturity of each type of Short-Term Investment (other than shares of money market funds) will be 397 calendar days.

4. Applicants believe that the separate purchase of Short-Term Investments by each Series could result in certain inefficiencies, a limitation on the return that the Series could otherwise achieve, and increased costs. Accordingly, applicants propose to deposit the Series' available cash balances in Joint Accounts and to invest the daily balance of the Joint Accounts in Short-Term Investments. Applicants also propose to deposit the Series' Cash Collateral in a separate Joint Account for investment in Short-Term Investments selected by the Adviser. The sole purpose of these Joint Accounts would be to provide a convenient means of aggregating what otherwise would be daily transactions for some or all of the Series to manage their daily account balances.

5. The Adviser will not participate monetarily in the Joint Accounts, nor will it receive an additional fee for the administration of the Accounts. The Adviser will be responsible for directing the investment of funds held by the Joint Accounts, establishing accounting and control procedures, operating the Joint Accounts in accordance with established procedures, and ensuring the fair treatment of each Series. The

⁴ The Custodian is not an affiliated person of either the Fund or the Adviser.

⁵ The Series will engage in hold-in-custody repurchase agreements (i.e., repurchase agreements where the counterpart or one of its affiliated persons may have possession of, or control over, the collateral subject to the agreement) only when cash is received very late in the business day and otherwise would be unavailable for investment.

¹ The Fund changed its name from foreign Fund, Inc. on January 2, 1997.

² The Adviser changed its name from BZW Barclays Global Fund Advisors on October 15, 1996.